Active ingredients

The drug ABRYSVO contains one active pharmaceutical ingredient (API):

RSV glycoprotein F antigen is designed to enhance antigen-specific cellular immune response and neutralizing antibodies response in individuals with pre-existing immunity against RSV. The adjuvant AS01E facilitates the recruitment and activation of antigen presenting cells carrying vaccine-derived antigens in the draining lymph node, which in turn leads to the generation of RSVPreF3-specific CD4+ T cells.

Read about RSV glycoprotein F antigen

Medication package inserts

Below package inserts are available for further reading:

Summary of Product Characteristics (SPC)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code
Group title
J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BX Other viral vaccines
Discover more medicines within J07BX05

Authorization and marketing

This brand name is authorized in the following countries: Austria Lithuania Romania United States

This drug has been assigned below unique identifiers within the countries it is being marketed:

Identification scheme
Valstybinė vaistų kontrolės tarnyba
Identifier(s): 1097701, 1097702, 1097703, 1097704, 1097705, 1097706
Agenția Națională a Medicamentului și a Dispozitivelor Medicale
Identifier(s): W69758001, W69758002, W69758003, W69758004, W69758005, W69758006
FDA, National Drug Code
Identifier(s): 0069-0207, 0069-0250, 0069-0344